Blog

The CADTH pCODR program is currently seeking nominations for a Health Economist to sit as a member of the pCODR Expert Review ...

The Pan Canadian Expert Review Committee has recommended the funding of pomalidomide (Pomalyst) for patients with relapsed and/or refractory multiple ...

The pCODR Expert Review Committee (pERC) has recommended against the funding of ofatumumab acetate (Arzerra) when used in combination with chlorambucil ...

[:content [\A \f \l \i \b \e \r \c \e \p \t \space \( \Z \a \l \t \r \a \p \) \  \i \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \e \d \space \f \o \r \space \u \s \e \space \w \i \t \h \i \n \space \N \H \S \space \S \c \o \t \l \a \n \d \space \f \o \r \space \u \s \e \  \i \n \space \c \o \m \b \i \n \a \t \i \o \n \space \w \i \t \h \space \i \r \i \n \o \t \e \c \a \n \/ \5 \- \f \l \u \o \r \o \u \r \a \c \i \l \/ \f \o \l \i \n \i \c \space \a \c \i \d \space \( \F \O \L \F \I \R \I \) \space \c \h \e \m \o \t \h \e \r \a \p \y \, \space \a \f \l \i \b \e \r \c \e \p \t \space \i \s \space \i \n \d \i \c \a \t \e \d " ..."]]

Effective April 1, 2015, the pCODR office will be moving to a new location in downtown Toronto -just a few ...

[:content [\N \I \C \E \space \h \a \s \space \i \s \s \u \e \d \  \n \e \w \space \p \r \e \l \i \m \i \n \a \r \y \space \g \u \i \d \a \n \c \e \  \t \h \a \t \space \d \o \e \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \space \P \f \i \z \e \r \' \s \space \b \o \s \u \t \i \n \i \b \space \( \B \o \s \u \l \i \f \) \space \f \o \r \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \p \r \e \v \i \o \u \s \l \y \space \t \r \e \a \t \e \d \space \c \h \r \o \n \i \c \space \m \y \e \l \o \i \d \space \l \e \u \k \a \e \m \i \a \space \( \C \M \L \) \. \  \B \o \s \u \t \i \n \i \b \space \i \s " ..."]]

People in Quebec living with chronic lymphocytic leukaemia (CLL) will now be able to access a new treatment option through the province's ...

[:content [\C \e \l \l \space \T \h \e \r \a \p \e \u \t \i \c \s \space \( \C \T \I \) \space \h \a \s \  \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \t \h \e \space \N \I \C \E \  \h \a \s \space \n \o \t \i \f \i \e \d \space \C \T \I \space \a \n \d \space \i \s \s \u \e \d \space \a \space \s \t \a \t \e \m \e \n \t \space \o \n \space \i \t \s \space \w \e \b \s \i \t \e \space \s \t \a \t \i \n \g \space \t \h \a \t \space \C \T \I \' \s \space \p \r \o \p \o \s \e \d " ..."]]

[:content [\B \o \e \h \r \i \n \g \e \r \space \I \n \g \e \l \h \e \i \m \space \( \C \a \n \a \d \a \) \space \L \t \d \. \space \h \a \s \space \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \G \i \o \t \r \i \f \  \( \a \f \a \t \i \n \i \b \) \space \t \a \b \l \e \t \s \space \f \o \r \space \o \r \a \l \space \u \s \e \, \space \a \s \space \a \space \n \e \w \space \t \r \e \a \t \m \e \n \t " ..."]]

[:content [\P \e \r \t \u \z \u \m \a \b \space \( \P \e \r \j \e \t \a \) \  \w \a \s \space \l \a \u \n \c \h \e \d \space \i \n \space \G \e \r \m \a \n \y \space \i \n \  \M \a \r \c \h \space \2 \0 \1 \3 \space \f \o \r \space \u \s \e \  \a \s \space \a \d \j \u \n \c \t \i \v \e \space \t \h \e \r \a \p \y \space \b \y \space \c \e \r \t \a \i \n \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \a \d \v \a \n \c \e \d \  \H \E \R \2 \- \p \o \s \i \t \i \v \e \space \b \r \e \a \s \t \space \c \a \n \c \e \r \. \  " ..."]]

CADTH is inviting stakeholders to attend an information and feedback session on 5 February 2015 regarding phase II of the ...

Merck Canada Inc. announced today that Keytruda (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. ...

[:content [\2 \1 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \â \€ \“ \space \E \f \f \e \c \t \i \v \e \space \1 \5 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \, \space \B \r \i \t \i \s \h \space \C \o \l \u \m \b \i \a \space \i \s \space \t \h \e \space \f \i \r \s \t \space \p \r \o \v \i \n \c \e \space \i \n \space \C \a \n \a \d \a \  \t \o \space \i \n \c \l \u \d \e \space \Z \y \t \i \g \a \  \( \a \b \i \r \a \t \e \r \o \n \e \space \a \c \e \t \a \t \e \) \space \o \n " ..."]]